SCHEMBL4881771

SCHEMBL4881771

C[C@@H]1CC(=O)CN1C(=O)OC(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.38
CHRM2 P08172 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38
SETD7 Q8WTS6 1/20 0.37
HSD11B1 P28845 1/20 0.36
USP2 O75604 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NR1H2 P55055 2/20 0.35
HSD17B10 Q99714 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
THRB P10828 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17709944 1.00 MAPK1 (0.38) MAPK1CHRM2CHRM1CHRM3SETD7
SCHEMBL891999 1.00 MAPK1 (0.38) MAPK1CHRM2CHRM1CHRM3SETD7
SCHEMBL23415868 0.85 CHRM2 (0.38) MAPK1CHRM2CHRM1CHRM3NR1H2
SCHEMBL19390105 0.85 CHRM2 (0.38) MAPK1CHRM2CHRM1CHRM3NR1H2
SCHEMBL1197535 0.83 SETD7 (0.40) MAPK1CHRM2CHRM1CHRM3SETD7
SCHEMBL432224 0.83 SETD7 (0.40) MAPK1CHRM2CHRM1CHRM3SETD7
SCHEMBL1197830 0.83 SETD7 (0.40) MAPK1CHRM2CHRM1CHRM3SETD7
SCHEMBL22620446 0.82 HSD17B10 (0.37) CHRM2CHRM1CHRM3HSD17B10
SCHEMBL8221891 0.81 TSHR (0.53) THRBMEN1KMT2A
SCHEMBL16903478 0.81 USP2 (0.37) MAPK1CHRM2CHRM1CHRM3SETD7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743447-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2026-05-20 EP disclosed
EP-4743178-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2026-05-20 EP disclosed
US-20260055116-A1 SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS KARUNA THERAPEUTICS INC (US) 2026-02-26 US disclosed
US-12421242-B2 Substituted tetrahydropyrrolo-pyridinone compounds and their use in treating medical conditions Karuna Therapeutics, Inc. (US) 2025-09-23 US disclosed
WO-2025016906-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2025-01-23 WO disclosed
WO-2025016909-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2025-01-23 WO disclosed
WO-2024220747-A2 FLUORINATED CYCLIC DERIVATIVES OF SULFONAMIDES AND SULFONES, AND COMPOSITIONS AND METHODS THEREOF Lysoway Therapeutics, Inc. (US) 2024-10-24 WO disclosed
US-20240336619-A1 SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS Karuna Therapeutics, Inc. 2024-10-10 US disclosed
CN-113444110-B Tetrahydropyrrolopyrazoles derivatives, preparation method and application thereof in medicines 江苏恒瑞医药股份有限公司 2023-05-12 CN disclosed
EP-3355935-B1 PYRROLOBENZODIAZEPINE ANTIBODY DRUG CONJUGATES AND METHODS OF USE HOFFMANN LA ROCHE (CH) 2020-10-21 EP disclosed
US-20190002452-A1 FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF GUANGZHOU HENOVCOM BIOSCIENCE CO. LTD. (CN) 2019-01-03 US disclosed
EP-3401315-A1 FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF Guangzhou Henovcom Bioscience Co. Ltd. (CN) 2018-11-14 EP disclosed
US-20170137405-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. 2017-05-18 US disclosed
US-9540343-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2017-01-10 US disclosed
US-8754107-B2 Aminopyrrolidines as chemokine receptor antagonists ABBVIE INC. (US) 2014-06-17 US disclosed
US-20140142085-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. (US) 2014-05-22 US disclosed
US-8729077-B2 Anti-viral compounds, compositions, and methods of use GLAXOSMITHKLINE LLC (US) 2014-05-20 US disclosed
US-20110224211-A1 Anti-Viral Compounds, Compositions, And Methods Of Use GLAXOSMITHKLINE LLC 2011-09-15 US disclosed
US-20080176883-A1 Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone ABBVIE INC. 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190002452-A1 FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF NR1H4, FXR1, GPBAR1 MAPK1 1045/4885CHRM2 1681/4885CHRM1 1576/4885
US-20080176883-A1 Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone MIF, CCL5, CCR2 MAPK1 237/4885CHRM2 3063/4885CHRM1 2236/4885
US-20110224211-A1 Anti-Viral Compounds, Compositions, And Methods Of Use HAVCR2, SARS1, MAVS MAPK1 3910/4885CHRM2 4465/4885CHRM1 4023/4885
US-20240336619-A1 SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS CHRM3, CHRM4, CHRM2 MAPK1 2907/4885CHRM2 3/4885CHRM1 5/4885
US-12421242-B2 Substituted tetrahydropyrrolo-pyridinone compounds and their use in treating medical conditions CHRM3, CHRM4, CHRM2 MAPK1 2907/4885CHRM2 3/4885CHRM1 5/4885
US-20170137405-A1 COMPOUNDS FOR THE TREATMENT OF HIV CCR5, NPC1, FURIN MAPK1 583/4885CHRM2 4698/4885CHRM1 4525/4885
US-20140142085-A1 COMPOUNDS FOR THE TREATMENT OF HIV CCR5, NPC1, FURIN MAPK1 583/4885CHRM2 4698/4885CHRM1 4525/4885
US-20260055116-A1 SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS CHRM3, CHRM2, CHRM1 MAPK1 1537/4885CHRM2 2/4885CHRM1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.